Show simple item record

dc.contributor.authorSaarelainen Laura
dc.contributor.authorTolppanen Anna-Maija
dc.contributor.authorKoponen Marjaana
dc.contributor.authorTanskanen Antti
dc.contributor.authorTiihonen Jari
dc.contributor.authorHartikainen Sirpa
dc.contributor.authorTaipale Heidi
dc.date.accessioned2018-01-08T12:40:27Z
dc.date.available2018-01-08T12:40:27Z
dc.date.issued2017
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/5130
dc.description.abstractObjective To investigate the risk of death associated with new benzodiazepine and related drug (BZDR) use in a nationwide cohort of persons with Alzheimer disease (AD). Methods The register-based MEDALZ cohort, including all community-dwelling Finns diagnosed with AD during 2005 to 2011 (n = 70 718), was used. Clinically verified AD diagnoses were obtained from the Special Reimbursement Register. Drug use periods were modeled from BZDR purchases, derived from the Prescription Register. To study new users, persons who had any BZDR use during the year preceding the AD diagnosis were excluded. For each person initiating BZDR use (n = 10 380), 2 nonusers (n = 20 760) were matched on age, gender, and time since AD diagnosis. The outcome was 180-day mortality, and BZDR use was compared with nonuse with Cox regression. Multivariable analyses were adjusted for Charlson comorbidity index, socioeconomic position, hip fractures, psychiatric disorders, substance abuse, stroke, and other psychotropic drug use. Results During the follow-up, 5 excess deaths per 100 person-years occurred during BZDR use in comparison to nonuse, and mortality rates were 13.4 (95% confidence interval [CI], 12.2-14.5) and 8.5 (95% CI, 7.9-9.1), respectively. Benzodiazepine and related drug use was associated with an increased risk of death (adjusted hazard ratio = 1.4 [95% CI, 1.2-1.6]), and the association was significant from the initiation of use. Benzodiazepine use was associated with an increased risk of death, whereas benzodiazepine-related drug use was not. Conclusions Benzodiazepine and related drug use was associated with an increased risk of death in persons with AD. Our results support treatment guidelines stating that nonpharmacological approaches should be the first-line option for symptomatic treatment of AD.en
dc.language.isoENen
dc.publisherWiley-Blackwellen
dc.relation.ispartofseriesINTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRYen
dc.relation.urihttp://dx.doi.org/10.1002/gps.4821en
dc.rightsAll rights reserveden
dc.subjectAlzheimer diseaseen
dc.subjectbenzodiazepinesen
dc.subjectcohort studyen
dc.subjectdrug safetyen
dc.subjectmortalityen
dc.subjectPrescription Registeren
dc.titleRisk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort studyen
dc.description.versionfinal draften
dc.contributor.departmentSchool of Pharmacy, Activitiesen
dc.contributor.departmentSchool of Medicine / Clinical Medicineen
uef.solecris.id51771794en
dc.type.publicationinfo:eu-repo/semantics/articleen
dc.rights.accessrights© John Wiley & Sons Ltden
dc.relation.doi10.1002/gps.4821en
dc.description.reviewstatuspeerRevieweden
dc.relation.issn0885-6230en
dc.relation.volume[Epub ahead of print 15 Nov 2017]en
dc.rights.accesslevelopenAccessen
dc.type.okmA1en
dc.type.versioninfo:eu-repo/semantics/acceptedVersionen
uef.solecris.openaccessEi


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record